{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=EyePoint+Pharmaceuticals%2C+Inc.",
    "query": {
      "sponsor": "EyePoint Pharmaceuticals, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 17,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=EyePoint+Pharmaceuticals%2C+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T19:13:13.483Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04290676",
      "title": "DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "DEXYCU (dexamethasone intraocular suspension) 9%.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 527,
      "start_date": "2019-11-13",
      "completion_date": "2020-05-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-26",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 22,
      "location_summary": "Dothan, Alabama • Hemet, California • Laguna Hills, California + 19 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rohnert Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04290676"
    },
    {
      "nct_id": "NCT07449936",
      "title": "COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema",
        "DME",
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "EYP-1901",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept (2.0 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2026-02-16",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 53,
      "location_summary": "Bakersfield, California • Encino, California • Glendale, California + 49 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07449936"
    },
    {
      "nct_id": "NCT04405245",
      "title": "Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Primary Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Latanoprost ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "AKB-9778 4%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2020-06-06",
      "completion_date": "2020-11-05",
      "has_results": true,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 21,
      "location_summary": "Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04405245"
    },
    {
      "nct_id": "NCT06099184",
      "title": "Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "EYP-1901",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2Mg/0.05Ml Inj,Oph",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2024-01-15",
      "completion_date": "2024-10-24",
      "has_results": false,
      "last_update_posted_date": "2025-03-04",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Lemont, Illinois • Hagerstown, Maryland + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Lemont",
          "state": "Illinois"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Reno",
          "state": "Nevada"
        },
        {
          "city": "Erie",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06099184"
    },
    {
      "nct_id": "NCT05381948",
      "title": "Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "EYP-1901",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2mg/0.05mL Inj,Oph",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2022-06-30",
      "completion_date": "2024-04-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 64 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05381948"
    },
    {
      "nct_id": "NCT06668064",
      "title": "A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wet Age Related Macular Degeneration",
        "wAMD"
      ],
      "interventions": [
        {
          "name": "EYP-1901",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept (2.0 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2024-10-22",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 76,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06668064"
    },
    {
      "nct_id": "NCT03197870",
      "title": "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonproliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "AKB-9778",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 167,
      "start_date": "2017-06-09",
      "completion_date": "2019-02-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 53,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03197870"
    },
    {
      "nct_id": "NCT02748512",
      "title": "Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "FAI Insert administered using the Mk II inserter",
          "type": "DRUG"
        },
        {
          "name": "FAI Insert administered using the Mk I inserter",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2016-02-23",
      "completion_date": "2017-08-17",
      "has_results": true,
      "last_update_posted_date": "2020-05-01",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 6,
      "location_summary": "Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Waltham",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Ladson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748512"
    },
    {
      "nct_id": "NCT04781335",
      "title": "\"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Dexycu",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care post operative eye drops (steroid, antibiotic, NSAID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Eye Institute of West Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-02-20",
      "completion_date": "2022-12-22",
      "has_results": false,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 1,
      "location_summary": "Largo, Florida",
      "locations": [
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04781335"
    },
    {
      "nct_id": "NCT05070728",
      "title": "Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uveitis",
        "Uveitis, Posterior",
        "Uveitis, Intermediate"
      ],
      "interventions": [
        {
          "name": "Sham Injector",
          "type": "DRUG"
        },
        {
          "name": "FAI Insert",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-10-13",
      "completion_date": "2023-04-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-10-05T19:13:13.483Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05070728"
    }
  ]
}